Home/Pipeline/CAM2029

CAM2029

Acromegaly & Neuroendocrine Tumors (NET)

Phase 3ActiveN/A

Key Facts

Indication
Acromegaly & Neuroendocrine Tumors (NET)
Phase
Phase 3
Status
Active
Company

About Camurus

Camurus is a fully integrated, commercial-stage biopharma focused on transforming chronic disease management through its proprietary FluidCrystal® long-acting injectable technology. The company has achieved commercial success with Buvidal® for opioid dependence and is advancing a diversified pipeline in pain, oncology, and endocrinology through a dual strategy of in-house development and strategic partnerships. With a validated platform, established commercial infrastructure in key markets, and a streamlined development model, Camurus is positioned to deliver significant value to patients, healthcare systems, and shareholders.

View full company profile

About Camurus

Camurus is a fully integrated, commercial-stage biopharma focused on transforming chronic disease management through its proprietary FluidCrystal® long-acting injectable technology. The company has achieved commercial success with Buvidal® for opioid dependence and is advancing a diversified pipeline in pain, oncology, and endocrinology through a dual strategy of in-house development and strategic partnerships. With a validated platform, established commercial infrastructure in key markets, and a streamlined development model, Camurus is positioned to deliver significant value to patients, healthcare systems, and shareholders.

View full company profile